Single Dose RSV Vaccine Found to Reduce Infections and Hospitalizations Among U.S. Veterans Over 60

A recent study conducted by the Veterans Affairs Portland Health Care System in Portland, Oregon, has found that a single dose of respiratory syncytial virus (RSV) vaccine provides significant protection against RSV infections and related complications among U.S. veterans aged 60 and older. The vaccine reduced RSV-related emergency visits, hospitalizations, and intensive care unit admissions over two respiratory illness seasons. However, researchers observed that the level of protection declined over time, with the most pronounced decrease occurring in immunocompromised individuals.

The study tracked the effectiveness of the vaccine across an 18-month period. While initial results showed strong protective effects during the first season following vaccination, immunity waned as time progressed into the second season. Immunocompromised participants experienced a sharper decline in protection compared to others in the study group. These findings highlight changes in vaccine efficacy over time and provide insights into how different populations may respond to RSV vaccination efforts. Researchers continue to analyze data to better understand long-term outcomes and potential strategies for improving sustained immunity against RSV infections.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

Related posts:

Leadership Expert Links Resilience to Self-Awareness, Teamwork, and Personal Worth. High-Resolution Map Identifies Mosquito Breeding Hotspots in Rio de Janeiro Using Open Geodata FDA Approves Leucovorin for Autism Cases Linked to Folate Transport Abnormalities ATP-Gated Switch Identified as Key Regulator of mRNA Export in Human Cells

Author

GOAI